Literature DB >> 23067225

Development of a fragile X syndrome (FXS) knowledge scale: towards a modified multidimensional measure of informed choice for FXS population carrier screening.

Alice G Ames1, Alice Jaques, Obioha C Ukoumunne, Alison D Archibald, Rony E Duncan, Jon Emery, Sylvia A Metcalfe.   

Abstract

BACKGROUND: Genetic carrier screening is increasingly possible for many conditions, but it is important to ensure decisions are informed. The multidimensional measure of informed choice (MMIC) is a quantitative instrument developed to evaluate informed choice in prenatal screening for Down syndrome, measuring knowledge, attitudes and uptake. To apply the MMIC in other screening settings, the knowledge scale must be modified.
OBJECTIVE: To develop and validate a modified MMIC knowledge scale for use with women undergoing carrier screening for fragile X syndrome (FXS). SETTING AND PARTICIPANTS: Responses to MMIC items were collected through questionnaires as part of a FXS carrier screening pilot study in a preconception setting in Melbourne, Australia.
DESIGN: Ten knowledge scale items were developed using a modified Delphi technique. Cronbach's alpha and factor analysis were used to validate the new FXS knowledge scale. We summarized the knowledge, attitudes and informed choice status based on the modified MMIC.
RESULTS: Two hundred and eighty-five women were recruited, 241 eligible questionnaires were complete for analysis. The FXS knowledge scale items measured one salient construct and were internally consistent (alpha = 0.70). 71% (172/241) of participants were classified as having good knowledge, 70% (169/241) had positive attitudes and 27% (65/241) made an informed choice to accept or decline screening. DISCUSSION AND
CONCLUSIONS: We present the development of a knowledge scale as part of a MMIC to evaluate informed choice in population carrier screening for FXS. This can be used as a template by other researchers to develop knowledge scales for other conditions for use in the MMIC.
© 2012 John Wiley & Sons Ltd.

Entities:  

Keywords:  decision-making; evaluation; fragile X syndrome; informed choice; measurement scales; screening

Mesh:

Year:  2012        PMID: 23067225      PMCID: PMC5060759          DOI: 10.1111/hex.12009

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  45 in total

Review 1.  Population screening in the age of genomic medicine.

Authors:  Muin J Khoury; Linda L McCabe; Edward R B McCabe
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

Review 2.  Informed choice for screening: implications for evaluation.

Authors:  Les Irwig; Kirsten McCaffery; Glenn Salkeld; Patrick Bossuyt
Journal:  BMJ       Date:  2006-05-13

Review 3.  Measures used in studies of informed decision making about cancer screening: a systematic review.

Authors:  Patricia Dolan Mullen; Jennifer Dacey Allen; Karen Glanz; Maria E Fernandez; Deborah J Bowen; Sandi L Pruitt; Beth A Glenn; Michael Pignone
Journal:  Ann Behav Med       Date:  2006-12

4.  The role of attitudes towards the targets of behaviour in predicting and informing prenatal testing choices.

Authors:  Louise D Bryant; Josephine M Green; Jenny Hewison
Journal:  Psychol Health       Date:  2010-12

5.  Do pregnant women in Greece make informed choices about antenatal screening for Down's syndrome? A questionnaire survey.

Authors:  Kleanthi Gourounti; Jane Sandall
Journal:  Midwifery       Date:  2007-02-20       Impact factor: 2.372

6.  "It's something I need to consider": decisions about carrier screening for fragile X syndrome in a population of non-pregnant women.

Authors:  Alison D Archibald; Alice M Jaques; Samantha Wake; Veronica R Collins; Jonathan Cohen; Sylvia A Metcalfe
Journal:  Am J Med Genet A       Date:  2009-12       Impact factor: 2.802

7.  A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study.

Authors:  Sylvia Metcalfe; Alice Jacques; Alison Archibald; Trent Burgess; Veronica Collins; Anna Henry; Kathleen McNamee; Leslie Sheffield; Howard Slater; Samantha Wake; Jonathan Cohen
Journal:  Genet Med       Date:  2008-07       Impact factor: 8.822

8.  Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk.

Authors:  Claire E Wakefield; Bettina Meiser; Judi Homewood; Robyn Ward; Sheridan O'Donnell; Judy Kirk
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

9.  Impact on informed choice of offering antenatal sickle cell and thalassaemia screening in primary care: a randomized trial.

Authors:  Katrina Brown; Elizabeth Dormandy; Erin Reid; Martin Gulliford; Theresa Marteau
Journal:  J Med Screen       Date:  2011       Impact factor: 2.136

10.  Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines.

Authors:  Kathryn E Kronquist; Stephanie L Sherman; Elaine B Spector
Journal:  Genet Med       Date:  2008-11       Impact factor: 8.822

View more
  7 in total

Review 1.  Advanced technologies for the molecular diagnosis of fragile X syndrome.

Authors:  Flora Tassone
Journal:  Expert Rev Mol Diagn       Date:  2015-10-21       Impact factor: 5.225

2.  "It gives them more options": preferences for preconception genetic carrier screening for fragile X syndrome in primary healthcare.

Authors:  Alison D Archibald; Chriselle L Hickerton; Samantha A Wake; Alice M Jaques; Jonathan Cohen; Sylvia A Metcalfe
Journal:  J Community Genet       Date:  2016-02-03

Review 3.  Measuring informed choice in population-based reproductive genetic screening: a systematic review.

Authors:  Alice Grace Ames; Sylvia Ann Metcalfe; Alison Dalton Archibald; Rony Emily Duncan; Jon Emery
Journal:  Eur J Hum Genet       Date:  2014-05-21       Impact factor: 4.246

4.  Informed decision making and psychosocial outcomes in pregnant and nonpregnant women offered population fragile X carrier screening.

Authors:  Sylvia A Metcalfe; Melissa Martyn; Alice Ames; Vicki Anderson; Alison D Archibald; Grad Dip Gen Couns; Rob Carter; Jonathan Cohen; Megan Cotter; M GenCouns; William Dang; Martin B Delatycki; Susan Donath; Samantha Edwards; PGrad Dip Educ; Grad Dip Gen Couns; Robin Forbes; Grad Dip Gen Couns; Mioara Gavrila; M MedSci; Jane Halliday; Chriselle Hickerton; Melissa Hill; Grad Dip Gen Couns; Lorilli Jacobs; PGrad Dip Ultrasound; Vicki Petrou; Grad Dip Gen Couns; Loren Plunkett; M GenCouns; Leslie Sheffield; F Racp; Alison Thornton; Grad Dip Gen Couns; Sandra Younie; PGrad Dip Hlth Econ; Jon D Emery
Journal:  Genet Med       Date:  2017-06-29       Impact factor: 8.822

5.  Offering fragile X syndrome carrier screening: a prospective mixed-methods observational study comparing carrier screening of pregnant and non-pregnant women in the general population.

Authors:  M Martyn; V Anderson; A Archibald; R Carter; J Cohen; M Delatycki; S Donath; J Emery; J Halliday; M Hill; L Sheffield; H Slater; F Tassone; S Younie; S Metcalfe
Journal:  BMJ Open       Date:  2013-09-10       Impact factor: 2.692

6.  Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy.

Authors:  Celine Lewis; Melissa Hill; Heather Skirton; Lyn S Chitty
Journal:  Eur J Hum Genet       Date:  2015-10-28       Impact factor: 4.246

7.  Does a web-based decision aid improve informed choice for fertility preservation in women with breast cancer (DECISIF)? Study protocol for a randomised controlled trial.

Authors:  Alexandra Benoit; Michael Grynberg; Rémy Morello; Nathalie Sermondade; Guillaume Grandazzi; Grégoire Moutel
Journal:  BMJ Open       Date:  2020-02-10       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.